Physician profile
Malory Berry
NPI 1356836332
$1,111.18
in general payments reported to CMS, 2019-2025
11 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $134 · 2023: $177 · 2024: $284 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.03 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $418.01 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $179.27 | 2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $152.99 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $99.22 | 2023-2025 | Rexulti |
| Abbott Laboratories | $48.11 | 2022-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $47.14 | 2025 | Cobenfy |
| Ardelyx, INC. | $40.10 | 2024-2025 | Ibsrela |
| Amgen INC. | $36.29 | 2024-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $36.28 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $36.04 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $17.73 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malory Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.